EED Antibody [E19A22]

Catalog No.: F4636

Application: Reactivity: Human, Mouse, Rat, Monkey

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000 IP1:50 IHC1:50 - 1:200 IF1:50 - 1:200 FCM1:50 - 1:200 CHIP1:100

Application
WB, IP, IHC, IF, FCM, ChIP

Source
Rabbit Monoclonal Antibody

Reactivity
Human, Mouse, Rat, Monkey

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
50-70 kDa

Datasheet & SDS

生物学的記述

Specificity
EED Antibody [E19A22] detects endogenous levels of total EED protein.

Clone
E19A22

Synonym(s)
Polycomb protein EED; hEED; Embryonic ectoderm development protein; WD protein associating with integrin cytoplasmic tails 1 (WAIT-1); EED

Background
EED (Embryonic Ectoderm Development protein) is a core non-catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), part of the Polycomb Group (PcG) family of epigenetic repressors that maintain developmental gene silencing. EED is composed of an unstructured N-terminal domain (residues 1–80) and a C-terminal seven-bladed β-propeller WD40 domain (residues 81–441), which forms a toroidal scaffold with four-stranded antiparallel β-sheets per blade. The top surface of the WD40 domain contains an aromatic cage (Tyr365, Tyr248, Trp364) that specifically recognizes H3K27me3 marks via cation-π interactions, while the bottom surface binds the N-terminus of EZH2 (residues 39–68) through hydrophobic contacts. EED facilitates PRC2 assembly (with EZH2, SUZ12, and RbAp46/48), allosterically activates EZH2’s H3K27 methyltransferase activity upon H3K27me3 binding to stimulate further methylation, reads and propagates existing H3K27 methylation marks, compacts chromatin, and enforces silencing of target genes such as Hox and INK4a/ARF, which are critical for stem cell maintenance, X-inactivation, and differentiation. Overexpression or mutation of EED can lead to PRC2 hyperactivation in cancers (e.g., leukemia, lymphoma, prostate cancer) and developmental disorders such as Weaver and Cohen-Gibson syndromes.

Background

EED (Embryonic Ectoderm Development protein) is a core non-catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), part of the Polycomb Group (PcG) family of epigenetic repressors that maintain developmental gene silencing. EED is composed of an unstructured N-terminal domain (residues 1–80) and a C-terminal seven-bladed β-propeller WD40 domain (residues 81–441), which forms a toroidal scaffold with four-stranded antiparallel β-sheets per blade. The top surface of the WD40 domain contains an aromatic cage (Tyr365, Tyr248, Trp364) that specifically recognizes H3K27me3 marks via cation-π interactions, while the bottom surface binds the N-terminus of EZH2 (residues 39–68) through hydrophobic contacts. EED facilitates PRC2 assembly (with EZH2, SUZ12, and RbAp46/48), allosterically activates EZH2’s H3K27 methyltransferase activity upon H3K27me3 binding to stimulate further methylation, reads and propagates existing H3K27 methylation marks, compacts chromatin, and enforces silencing of target genes such as Hox and INK4a/ARF, which are critical for stem cell maintenance, X-inactivation, and differentiation. Overexpression or mutation of EED can lead to PRC2 hyperactivation in cancers (e.g., leukemia, lymphoma, prostate cancer) and developmental disorders such as Weaver and Cohen-Gibson syndromes.

References
[1] Han Z, et al. Structure. 2007 Oct;15(10):1306-15. [2] Xu C, et al. Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19266-71.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%